Vertex Pharmaceuticals, Inc. (VRTX)
Current
- (-)
After Hours
Rating Performance
Rating Return
+4.32% vs
Rating Accuracy
50.0% (1 of 2*)
Rating Return
+8.65% vs
Rating Accuracy
66.67% (2 of 3*)
Rating Return
+8.65% vs
Rating Accuracy
66.67% (2 of 3*)
Rating Return
+8.65% vs
Rating Accuracy
66.67% (2 of 3*)
FV Performance
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
+15.05%
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
+14.33%
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
+14.33%
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
+43.02%
*There is a current rating on the stock that is included in these numbers based on its performance so far
About
CEO
Reshma Kewalramani
Employees
3,000
Industry
Respiratory System Biopharmaceuticals
Sector
Healthcare
Headquarters
Boston
Exchange
NASDAQ
Website
http://www.vrtx.comSummary Stats
Market Cap
80.5B
Revenue
8.93B
Net Income
3.32B
EPS
$12.82
Price-to-Earnings
24.43
Price-to-Book
5.79
Debt-to-Equity
0.31
News
Analyst Ratings
Price targets projected by 24 analysts
High
$356.00
Average
$287.75
Low
$220.00
Ratings calculated by 28 analysts
Buy
22
Hold
6
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q4 2022
Above by $0.25
$3.76 +7.1%
3.51
3.37
Up 11%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--